Empatica Parkinson’s Monitoring: FDA Clears a Wearable Platform for Tremor, Dyskinesia and Slowness
Empatica’s Health Monitoring Platform for Parkinson’s is now FDA cleared, bringing wrist worn, clinically validated symptom tracking from research studies into routine Parkinson’s care.
Presented By Our Partners
Quick answer, verified October 20, 2026
Empatica announced on August 19, 2026, that its Health Monitoring Platform for Parkinson’s received FDA 510(k) clearance. The system combines Empatica’s clinical grade wearable with algorithms from PKG Health, which Empatica acquired in 2025, to give clinicians objective, at home measures of Parkinson’s symptoms and treatment response.
- What it measures: bradykinesia, dyskinesia, tremor, sleep, motor fluctuations, gait and medication compliance.
- How it works: a wearable, a patient app, secure cloud processing and a clinician portal.
- Evidence: the PKG algorithms appear in more than 70 peer reviewed publications and are used at more than 150 hospitals and clinical sites.
- Who gets it: people with Parkinson’s through their care team or research programs, not as an off the shelf consumer device.
- Milestone: Empatica’s twelfth FDA clearance.
The short verdict
Parkinson’s symptoms change hour to hour, often in step with medication timing, yet most treatment decisions rest on a short clinic visit and a patient’s memory of the past few weeks. Continuous wrist based measurement of slowness, involuntary movement and tremor fills that gap with objective data. Empatica’s clearance matters because it pulls a research proven approach into a regulated clinical product with a clinician facing workflow.
What the platform tracks
The Empatica Health Monitoring Platform for Parkinson’s reports validated measures of:
Featured Partner
Invest in the Infrastructure Behind Modern Medicine
As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.
Learn More →
- Bradykinesia: slowness of movement, a core Parkinson’s symptom.
- Dyskinesia: involuntary movements, often a side effect of levodopa therapy.
- Tremor.
- Motor fluctuations: how symptoms rise and fall across the day.
- Sleep and gait.
- Medication compliance: whether doses are taken as planned.
According to Empatica, the PKG algorithms can provide more than 30 validated movement disorder measures.
Why it could change treatment decisions
Research led by Dr. Ritesh Ramdhani, who directs the Deep Brain Stimulation Program and the Parkinson’s and Movement Disorders Division at Northwell Health, found that adding wearable derived PKG data to patient demographics and clinical scores improved the accuracy of predicting an optimal medication regimen by 33 percent, reaching 86.9 percent accuracy. Dr. Ramdhani said wearable monitoring helps clinicians understand how symptoms change daily and respond to treatment.
Where it came from
Empatica, based in the Boston area, built its business on clinical grade wearables for epilepsy and sleep monitoring. In 2025 it acquired PKG Health, whose Personal KinetiGraph (PKG) measures have been widely used by pharmaceutical companies, hospitals and universities, including in clinical trials of new Parkinson’s treatments. The new clearance combines PKG’s measures with Empatica’s wearables and connected platform.
How to get it
The platform is built around a clinician portal, so access runs through neurologists, movement disorder clinics and research programs. Empatica has not published consumer pricing. If you or a family member has Parkinson’s, ask your neurologist whether remote symptom monitoring is available through their clinic or a study.
How it compares with consumer wearables
General smartwatches can count steps and sometimes detect tremor like movement, but they are not cleared to measure Parkinson’s symptoms. Empatica’s platform is a regulated medical system whose measures have been validated against clinical assessments. For broader context on AI and neurology devices, see our overview of FDA authorized AI in neurology.
Limitations and open questions
- Access: availability depends on whether your care team offers it.
- Coverage: insurance coverage and out of pocket costs have not been published.
- Interpretation: data supports, but does not replace, a clinician’s assessment.
Frequently asked questions
Is Empatica FDA cleared for Parkinson’s?
Yes. Empatica announced FDA 510(k) clearance for its Health Monitoring Platform for Parkinson’s on August 19, 2026.
What does the Empatica Parkinson’s platform measure?
Bradykinesia, dyskinesia, tremor, sleep, motor fluctuations, gait and medication compliance, using wearable data and PKG algorithms.
Can I buy Empatica’s Parkinson’s monitor myself?
It is designed for use through clinicians and research programs with a clinician portal. Ask your neurologist about access.
Sources
- Empatica: FDA clearance for Parkinson’s monitoring (August 19, 2026)
- Indian Pharma Post (August 21, 2026)
- FDA 510(k) database: K260374
This article is for general information and is not medical advice.
Similar Posts
Blood Tests Are Rewriting Alzheimer’s Detection: How P-Tau217, Finger Prick Diagnostics, and Lithium Science Are Transforming Cognitive Aging
A convergence of 2026 studies in Nature Medicine and Nature Aging is transforming Alzheimer’s detection. The p-tau217 blood test clock predicts symptom onset within three to four years, a finger…
Airofit PRO Respiratory Trainer Review: App Guided Breathing Muscle Training for Athletes and Respiratory Health
The Airofit PRO combines adjustable respiratory resistance with real time Bluetooth biofeedback to strengthen the muscles that power every breath you take. Presented By Our Partners The diaphragm is the…
Beyond Inheritance by Roxanne Khamsi: A Review
An inaugural entry in HD Reads. Roxanne Khamsi’s Beyond Inheritance is the most important popular biology book of 2026 to date, and the foundation text for a way of seeing…
Withings Thermo Smart Thermometer: FDA-Cleared Temporal Artery Temperature Monitoring
Fever is the oldest vital sign humans have measured, yet most households still rely on technology that has barely changed in a century. A connected thermometer asks whether temperature data,…
A Nasal Spray That Reverses Brain Aging: The Texas A&M Breakthrough Reshaping Alzheimer’s Research
A two-dose nasal spray built from human neural stem cell-derived particles silenced the inflammation signals that drive cognitive decline, restored memory in aged mice, and is now being positioned for…
The Daily Rounds: Longevity & Health Care Brief | May 4, 2026
💊 Semaglutide's Psychiatric Signal — A 100,000-person Lancet study found GLP-1 drugs are associated with 44% lower depression risk, 42% fewer psychiatric hospitalizations, and 47% fewer substance use disorder admissions. ☕ Coffee as a Gut-Brain Intervention — A Nature Communications trial confirmed daily coffee, including decaf, reshapes the gut microbiome in ways that demonstrably improve mood, lower anxiety, and enhance memory. ⚠️ Pesticide Mixtures Exceed Safe Thresholds — Individually non-carcinogenic pesticides combine to raise cancer risk by 150% in high-exposure regions, demanding mixture-based regulatory evaluation. 🧬 MLKL Death Protein Drives Immune Aging — A death protein damages stem cell mitochondria without killing cells, progressively weakening immune resilience with age, and can be targeted to preserve regenerative capacity. 💰 AI Drug Pipelines Hit Commercial Scale — Eli Lilly's $2.75 billion Insilico deal and the NVIDIA-Lilly AI lab mark the pharmaceutical industry's decisive shift from AI experiments to AI-native drug development at scale.
